DOCS
Doximity, Inc. Healthcare - Health Information Services Investor Relations →
Doximity, Inc. (DOCS) closed at $24.41 as of 2026-03-20, trading 38.4% below its 200-week moving average of $39.63. This places DOCS in the extreme value zone. The stock moved further from the line this week, up from -38.6% last week. With a 14-week RSI of 8, DOCS is in oversold territory.
Trading volume is running at 0.9x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.76 ratio) is neutral — neither side is clearly dominating.
Over the past 199 weeks of data, DOCS has crossed below its 200-week moving average 2 times. On average, these episodes lasted 64 weeks. The average one-year return after crossing below was -13.1%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $4.6 billion, DOCS is a mid-cap stock. The company generates a free cash flow yield of 4.7%. Return on equity stands at 23.8%, indicating strong profitability. The stock trades at 4.6x book value.
DOCS passes our Buffett quality screen: high return on equity, low debt, and positive free cash flow.
Over the past 3.9 years, a hypothetical investment of $100 in DOCS would have grown to $64, compared to $166 for the S&P 500. DOCS has returned -10.7% annualized vs 13.8% for the index, underperforming the broader market over this period.
Free cash flow has been growing at a 30.2% compound annual rate, with 4 consecutive years of positive cash generation. A business generating more cash every year while trading below its 200-week moving average is exactly the kind of disconnect value investors look for.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: DOCS vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After DOCS Crosses Below the Line?
Across 2 historical episodes, buying DOCS when it crossed below its 200-week moving average produced an average return of -13.0% after 12 months (median -13.0%), compared to +3.0% for the S&P 500 over the same periods. After 24 months, the average return was -27.0% vs +32.0% for the index.
Each line shows $100 invested at the moment DOCS crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
DOCS has crossed below its 200-week MA 2 times with an average 1-year return of +-13.1% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| May 2022 | Sep 2024 | 119 | 54.0% | -13.1% | -35.8% |
| Jan 2026 | Ongoing | 8+ | 38.6% | Ongoing | -34.9% |
| Average | 64 | — | +-13.1% | — |
Frequently Asked Questions
Is DOCS below its 200-week moving average?
Yes. As of 2026-03-20, Doximity, Inc. (DOCS) is trading 38.4% below its 200-week moving average of $39.63. The current price is $24.41.
What is DOCS's 200-week moving average price?
Doximity, Inc.'s 200-week moving average is $39.63 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when DOCS drops below its 200-week moving average?
DOCS has crossed below its 200-week moving average 2 times in our data. The average one-year return after these crossings was -13.1%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 64 weeks on average.
Is DOCS a good value right now?
Here's what our data says about DOCS as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 8 (oversold). Free cash flow yield is 4.7%. Return on equity is 23.8%. Price-to-book is 4.6x. This is not a buy or sell recommendation — always do your own research.
How does DOCS compare to the S&P 500?
Over the past 3.9 years, $100 invested in DOCS would have grown to $64, compared to $166 for the S&P 500. That's -10.7% annualized vs 13.8% for the index. DOCS has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20